Insulin glargine

Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells[1][2][3][4].

Product Specifications

CAS Number

[160337-95-1]

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Akt; Insulin Receptor

Type

Peptides

Related Pathways

PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/insulin-glargine.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H]([C@H](O)C)C(N6[C@@H](CCC6)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC7=O)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC8=O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CO)C(N[C@@H](CC9=CNC=N9)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC%10=CC=C(C=C%10)O)C(N[C@@H](CC(C)C)C(N[C@H]7C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC%11=CNC=N%11)NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC([C@H](C(C)C)NC([C@H](CC%12=CC=CC=C%12)N)=O)=O)=O)=O)=O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H]8[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)CN

Molecular Formula

C267H404N72O78S6

Molecular Weight

6062.89

Precautions

H302, H315, H319, H335

References & Citations

[1]Hwang HG, et al. Recombinant Glargine Insulin Production Process Using Escherichia coli. J Microbiol Biotechnol. 2016;26 (10) :1781-1789. |[2]Stammberger I, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002 May-Jun;21 (3) :171-9.|[3]Li Y, et al. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. Med Sci Monit. 2018 May 19;24:3293-3300.|[4]Liu S, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011 Feb;91 (2) :177-82.